<div id="readability-page-1"><p>In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on NextCure, with a price target of <span id="expert-recommendation-target">$15.00</span>.</p><h3>TipRanks Black Friday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for the data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>According to TipRanks, Tenthoff is an analyst with an average return of <span>-8.8%</span> and a 33.95% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arvinas Holding Company, and Moderna.</p> <p>Currently, the analyst consensus on NextCure is a Moderate Buy with an average price target of $19.00.</p></div>

NXTC

<p>Piper Sandler's Edward Tenthoff reiterated a Buy rating on NextCure (NXTC) with a $15.00 price target. Tenthoff, who covers the Healthcare sector, has an average return of -8.8% and a 33.95% success rate. The analyst consensus on NextCure is a Moderate Buy with an average price target of $19.00.</p>

Piper Sandler Keeps Their Buy Rating on NextCure (NXTC)